Kiora Selling General Administrative from 2010 to 2025

KPRX Stock  USD 3.69  0.10  2.64%   
Kiora Pharmaceuticals Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative will likely drop to about 4.8 M in 2025. During the period from 2010 to 2025, Kiora Pharmaceuticals Selling General Administrative regression line of annual values had r-squared of  0.52 and arithmetic mean of  4,289,733. View All Fundamentals
 
Selling General Administrative  
First Reported
2013-03-31
Previous Quarter
1.5 M
Current Value
1.4 M
Quarterly Volatility
425.1 K
 
Yuan Drop
 
Covid
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.39. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Kiora Pharmaceuticals over the last few years. It is Kiora Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Kiora Selling General Administrative Regression Statistics

Arithmetic Mean4,289,733
Geometric Mean4,011,916
Coefficient Of Variation36.90
Mean Deviation1,163,218
Median4,636,408
Standard Deviation1,582,862
Sample Variance2.5T
Range6.3M
R-Value0.72
Mean Square Error1.3T
R-Squared0.52
Significance0
Slope239,565
Total Sum of Squares37.6T

Kiora Selling General Administrative History

20254.8 M
20245.4 M
20234.7 M
20228.3 M
20215.3 M
20204.7 M
20194.4 M

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative5.4 M4.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.